Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 18/20 | 0.80 |
| ▸ | ESR2 | Q92731 | 17/20 | 0.80 |
| ▸ | MLNR | O43193 | 1/20 | 0.52 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.52 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.52 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.52 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.52 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.52 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.52 |
| ▸ | DRD2 | P14416 | 1/20 | 0.52 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.52 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.52 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.52 |
| ▸ | NPY1R | P25929 | 1/20 | 0.52 |
| ▸ | HTR2A | P28223 | 1/20 | 0.52 |
| ▸ | HTR2C | P28335 | 1/20 | 0.52 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22297087 | 1.00 | ESR1 (0.80) | ESR1ESR2MLNRNR1I2NR3C1 | |
| SCHEMBL669065 | 0.89 | ESR1 (1.00) | ESR1ESR2MLNRNR1I2NR3C1 | |
| SCHEMBL30583267 | 0.88 | ESR1 (1.00) | ESR1ESR2MLNRNR1I2NR3C1 | |
| Hydrochloric Acid SCHEMBL3776559 | 0.88 | ESR1 (0.98) | ESR1ESR2MLNRNR1I2NR3C1 | |
| SCHEMBL4325515 | 0.88 | ESR1 (1.00) | ESR1ESR2MLNRNR1I2NR3C1 | |
| SCHEMBL20234947 | 0.87 | ESR1 (0.73) | ESR1ESR2 | |
| SCHEMBL20234943 | 0.86 | ESR1 (0.84) | ESR1ESR2MLNRNR1I2NR3C1 | |
| SCHEMBL19439314 | 0.83 | ESR1 (0.78) | ESR1ESR2 | |
| SCHEMBL5605352 | 0.83 | ESR1 (0.78) | ESR1ESR2MLNRNR1I2NR3C1 | |
| SCHEMBL22297339 | 0.82 | ESR1 (0.59) | ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250320195-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS OPERATIONS INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-12172981-B2 | Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders | ARVINAS OPERATIONS, INC. (US) | 2024-12-24 | — | — | US | disclosed |
| CN-118834201-A | Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degrading agents | 阿尔维纳斯运营股份有限公司 | 2024-10-25 | — | — | CN | disclosed |
| CN-110291087-B | Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degrading agents | 阿尔维纳斯运营股份有限公司 | 2024-07-09 | — | — | CN | disclosed |
| US-20240076281-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS OPERATIONS, INC. (US) | 2024-03-07 | — | — | US | disclosed |
| EP-3689868-B1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS OPERATIONS INC (US) | 2023-09-27 | — | — | EP | disclosed |
| EP-3689868-B1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS OPERATIONS INC (US) | 2023-09-27 | — | — | EP | disclosed |
| US-11597720-B2 | Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders | ARVINAS OPERATIONS, INC. (US) | 2023-03-07 | — | — | US | disclosed |
| CN-114656452-B | Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders | 阿尔维纳斯运营股份有限公司 | 2023-01-17 | — | — | CN | disclosed |
| US-20220388984-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS OPERATIONS, INC. | 2022-12-08 | — | — | US | disclosed |
| EP-3689868-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | Arvinas Operations, Inc. (US) | 2020-08-05 | — | — | EP | disclosed |
| EP-3689868-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | Arvinas Operations, Inc. (US) | 2020-08-05 | — | — | EP | disclosed |
| CN-111454248-A | Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders | 阿尔维纳斯运营股份有限公司 | 2020-07-28 | — | — | CN | disclosed |
| US-10647698-B2 | Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders | ARVINAS OPERATIONS, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-10647698-B2 | Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders | ARVINAS OPERATIONS, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| EP-3548483-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | Arvinas Operations, Inc. (US) | 2019-10-09 | — | — | EP | disclosed |
| US-20180155322-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS OPERATIONS, INC. | 2018-06-07 | — | — | US | disclosed |
| US-20180155322-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS OPERATIONS, INC. | 2018-06-07 | — | — | US | disclosed |
| WO-2018102725-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | Arvinas, Inc. (US) | 2018-06-07 | — | — | WO | disclosed |
| WO-2018102725-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | Arvinas, Inc. (US) | 2018-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240076281-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | MDM2, CRBN, VHL | ESR1 13/4885ESR2 8/4885MLNR 2259/4885 |
| US-20220388984-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | MDM2, CRBN, VHL | ESR1 13/4885ESR2 8/4885MLNR 2259/4885 |
| US-12172981-B2 | Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders | MDM2, CRBN, VHL | ESR1 13/4885ESR2 8/4885MLNR 2259/4885 |
| US-20250320195-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | MDM2, CRBN, VHL | ESR1 13/4885ESR2 8/4885MLNR 2259/4885 |
| US-11597720-B2 | Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders | MDM2, CRBN, VHL | ESR1 13/4885ESR2 8/4885MLNR 2259/4885 |
| US-20180155322-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | MDM2, CRBN, VHL | ESR1 13/4885ESR2 8/4885MLNR 2259/4885 |
| US-10647698-B2 | Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders | MDM2, CRBN, VHL | ESR1 13/4885ESR2 8/4885MLNR 2259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.